✦ LIBER ✦

New oral Xa and IIa inhibitors: updates on clinical trial results

✍ Scribed by Sylvia Haas

Book ID: 106543975
Publisher: Springer US
Year: 2007
Tongue: English
Weight: 255 KB
Volume: 25
Category: Article
ISSN: 0929-5305
DOI: 10.1007/s11239-007-0108-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy and tolerability of vardena

The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial

✍ Porst, H; Rosen, R; Padma-Nathan, H; Goldstein, I; Giuliano, F; Ulbrich, E; Band 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 128 KB

Randomized trial of fenretinide (4-HPR)

Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: Long-term results

✍ Fausto Chiesa; Nicoletta Tradati; Roberto Grigolato; Patrizia Boracchi; Elia Big 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 84 KB

## Abstract We assessed the efficacy of fenretinide at preventing relapses, new lesions and carcinomas after surgical excision of oral leukoplakia. In a controlled multicenter study, 170 patients operated on for oral leukoplakias with benign postoperative histology were randomized to 200 mg fenreti

Rofecoxib, a specific inhibitor of cyclo

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip

✍ Grant W. Cannon; Jacques R. Caldwell; Peter Holt; Barry McLean; Beth Seidenberg; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 3 views